First transcatheter aortic valve implantation for severe pure aortic regurgitation in Asia
Adjust font size :   fontsmall   fontbig
 

Chiam PT, Ewe SH, Chua YL, Lim YT
Correspondence: Dr Paul TL Chiam, paul.chiam.t.l@nhcs.com.sg

ABSTRACT
Transcatheter aortic valve implantation (TAVI) has become the standard of care for inoperable patients with symptomatic severe aortic stenosis (AS), and an alternative to open aortic valve replacement for patients at high surgical risk. TAVI has also been performed in several groups of patients with off-label indications such as severe bicuspid AS, and as a valve-in-valve therapy for a degenerated surgical bioprosthesis. Although TAVI with CoreValve® prosthesis is technically challenging, and global experience in the procedure is limited, the procedure could be a treatment option for well-selected patients with severe pure aortic regurgitation (AR). Herein, we report Asia’s first case of TAVI for severe pure AR in a patient who was at extreme surgical risk, with good clinical outcome at six months.

Keywords: 
aortic valve regurgitation, aortic valve stenosis, catheter, prosthesis, transcatheter aortic valve implantation
Singapore Med J 2014; 55(2): 103-105; http://dx.doi.org/10.11622/smedj.2014022

[Full Text PDF]